“Pro” active: The peptidylglycine α-amidating monooxygenase (PAM) is introduced as a novel bioactivating enzyme of O-carboxymethylamidoximes and N-hydroxyguanidines—prodrug analogues of amidines and guanidines, respectively. Proof-of-concept is demonstrated in vitro with model compounds, as well as the antiprotozoic agent pentamidine.
No takes yet. Share an insight, caveat, or question.
Schade et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: